Drug intelligence / Profile preview

SHR-2001

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

SHR-2001 is an antibody-cytokine fusion protein developed by Guangdong Hengrui Pharmaceutical. It is administered subcutaneously and is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The drug is intended for the treatment of autoimmune diseases. As of now, there are no similar drugs approved for marketing globally[1][2][5].

Beyond the preview

Go deeper on SHR-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2001.

Explore the full profile